WO2010002818A3 - Vaccin antipaludéen de nanoparticules de polypeptide auto-assemblées - Google Patents

Vaccin antipaludéen de nanoparticules de polypeptide auto-assemblées Download PDF

Info

Publication number
WO2010002818A3
WO2010002818A3 PCT/US2009/049131 US2009049131W WO2010002818A3 WO 2010002818 A3 WO2010002818 A3 WO 2010002818A3 US 2009049131 W US2009049131 W US 2009049131W WO 2010002818 A3 WO2010002818 A3 WO 2010002818A3
Authority
WO
WIPO (PCT)
Prior art keywords
self
coil domain
assembling
nanoparticles
coiled
Prior art date
Application number
PCT/US2009/049131
Other languages
English (en)
Other versions
WO2010002818A2 (fr
Inventor
David Lanar
Peter Burkhard
Original Assignee
United States Army As Represented By The Secretar Of The Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Army As Represented By The Secretar Of The Army filed Critical United States Army As Represented By The Secretar Of The Army
Priority to US13/056,298 priority Critical patent/US20120015000A1/en
Priority to EP09774269.6A priority patent/EP2313108A4/fr
Publication of WO2010002818A2 publication Critical patent/WO2010002818A2/fr
Publication of WO2010002818A3 publication Critical patent/WO2010002818A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des nanoparticules de polypeptide auto-assemblées (SAPN) fonctionnalisées, et des procédés d’utilisation de ces nanoparticules pour la vaccination contre le paludisme. La SAPN fonctionnalisée comprend un noyau auto-assemblé, et au moins un épitope fusionné avec le noyau auto-assemblé. Le noyau auto-assemblé comprend un domaine de superhélice pentamérique, un domaine de superhélice trimérique, et un lieur. Le lieur relie le domaine de superhélice pentamérique et le domaine de superhélice trimérique. Des séquences particulières des épitopes utilisés dans le vaccin proviennent du parasite Plasmodium.
PCT/US2009/049131 2008-06-30 2009-06-29 Vaccin antipaludéen de nanoparticules de polypeptide auto-assemblées WO2010002818A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/056,298 US20120015000A1 (en) 2008-06-30 2009-06-29 Malaria vaccine of self-assembling polypeptide nanoparticles
EP09774269.6A EP2313108A4 (fr) 2008-06-30 2009-06-29 Vaccin antipaludéen de nanoparticules de polypeptide auto-assemblées

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7696308P 2008-06-30 2008-06-30
US61/076,963 2008-06-30

Publications (2)

Publication Number Publication Date
WO2010002818A2 WO2010002818A2 (fr) 2010-01-07
WO2010002818A3 true WO2010002818A3 (fr) 2010-05-27

Family

ID=41466552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/049131 WO2010002818A2 (fr) 2008-06-30 2009-06-29 Vaccin antipaludéen de nanoparticules de polypeptide auto-assemblées

Country Status (3)

Country Link
US (1) US20120015000A1 (fr)
EP (1) EP2313108A4 (fr)
WO (1) WO2010002818A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011018499A1 (de) * 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
CA2878427A1 (fr) * 2012-07-26 2014-01-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccin a proteine de fusion multimerique et produit immunotherapeutique
US10248758B2 (en) * 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
JP2016532712A (ja) * 2013-09-05 2016-10-20 イミューン デザイン コーポレイション 薬物中毒に対するワクチン組成物
WO2015164798A1 (fr) * 2014-04-25 2015-10-29 Tria Bioscience Corp. Compositions de support d'haptène synthétique et procédés
EP3964532A4 (fr) * 2019-04-29 2023-06-07 Academy of Military Medical Sciences Protéine de fusion pouvant s'auto-assembler en nanoparticules protéiques et utilisation associée
WO2022106860A1 (fr) * 2020-11-20 2022-05-27 Pécsi Tudományegyetem Peptides recombinants destinés à être utilisés en thérapie
WO2024099273A1 (fr) * 2022-11-07 2024-05-16 厦门大学 Protéine de fusion et antigène granulé la comprenant
WO2024151580A1 (fr) * 2023-01-11 2024-07-18 University Of Washington Conception de pièges à peptides amyloïdogènes

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020172692A1 (en) * 1996-08-02 2002-11-21 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
US20030054337A1 (en) * 2000-08-16 2003-03-20 Birkett Ashley J. Malaria immunogen and vaccine
US20030091593A1 (en) * 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
US20030157135A1 (en) * 2001-07-25 2003-08-21 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US20030216342A1 (en) * 1998-05-13 2003-11-20 Fikes John D. Expression vectors for stimulating an immune response and methods of using the same
US20040197876A1 (en) * 2001-05-08 2004-10-07 Jurg Tschopp Recombinant fusion proteins and the trimers thereof
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US20070014804A1 (en) * 2003-02-17 2007-01-18 Peter Burkhard Peptidic nanoparticles as drug delivery and antigen display systems

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049197A1 (en) * 1993-09-14 2005-03-03 Epimmune Inc. Induction of immune response against desired determinants
WO2009109428A2 (fr) * 2008-02-01 2009-09-11 Alpha-O Peptides Ag Nanoparticules peptidiques à auto-assemblage utiles comme vaccins

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020172692A1 (en) * 1996-08-02 2002-11-21 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
US20030216342A1 (en) * 1998-05-13 2003-11-20 Fikes John D. Expression vectors for stimulating an immune response and methods of using the same
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US20030054337A1 (en) * 2000-08-16 2003-03-20 Birkett Ashley J. Malaria immunogen and vaccine
US20040197876A1 (en) * 2001-05-08 2004-10-07 Jurg Tschopp Recombinant fusion proteins and the trimers thereof
US20030157135A1 (en) * 2001-07-25 2003-08-21 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US20030091593A1 (en) * 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US20070014804A1 (en) * 2003-02-17 2007-01-18 Peter Burkhard Peptidic nanoparticles as drug delivery and antigen display systems

Also Published As

Publication number Publication date
US20120015000A1 (en) 2012-01-19
WO2010002818A2 (fr) 2010-01-07
EP2313108A4 (fr) 2013-06-12
EP2313108A2 (fr) 2011-04-27

Similar Documents

Publication Publication Date Title
WO2010002818A3 (fr) Vaccin antipaludéen de nanoparticules de polypeptide auto-assemblées
JP2012074699A5 (fr)
WO2008122769A3 (fr) Vecteur adénoviral codant l'antigène du paludisme
WO2011032161A8 (fr) Vaccins dirigés contre les cellules de langerhans
WO2012058517A3 (fr) Membranes à nanofils céramiques et procédés de fabrication associés
WO2009039229A3 (fr) Procédé pour conférer une réponse immune protectrice à un norovirus
HK1215051A1 (zh) 交叉反應性增強的包含複合衣殼氨基酸序列的病毒樣顆粒
HK1156969A1 (zh) 新的流感病毒免疫表位
HK1179508A1 (zh) 採用免疫原性的瘧原蟲環子孢子蛋白表位的重組腺病毒的修飾
EP2089051A4 (fr) Augmentation de l'immunogenicite des antigenes associes aux tumeurs par l'adjonction d'epitopes gal
WO2011016933A3 (fr) Procédé et appareil pour disposer un conducteur dans une tubulure
WO2011034605A3 (fr) Complexes protéiques contenant une super-hélice et/ou une attache et leurs utilisations
WO2013068563A3 (fr) Molécules d'anticorps ayant une spécificité pour ox40 humain
WO2009007244A3 (fr) Nouveau vecteur viral d'expression de séquences hétérologues
JP2011523851A5 (fr)
WO2010027818A3 (fr) Epitope conservé d'hémagglutinine, anticorps contre l'épitope et procédés d'utilisation
MX359598B (es) Collar de limite mejorado.
MX2010001752A (es) Vacunas.
WO2011150213A3 (fr) Déploiement d'une pompe de fond de trou au moyen de câble
WO2010133465A3 (fr) Procédé de préparation de nanoparticules par utilisation de mini-émulsions
HK1165694A1 (zh) 密碼子優化的乙型肝炎病毒核心抗原
WO2011050006A3 (fr) Jack enregistré à verrouillage de cartouche et procédé d'utilisation associé
PT2222335T (pt) Composições imunogénicas e de vacina do vírus da língua azul, métodos de utilização e métodos de produção das mesmas
HUE041481T2 (hu) IB-QX-szerû törzsekbõl származó, fertõzõ bronchitis elleni oltóanyagok
JP2015503892A5 (fr)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09774269

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13056298

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2009774269

Country of ref document: EP